Development of novel medication for osteoporosis which focuses on the renin angiotensin system in osteoblast and osteocyte

• Project/Area Number: 26861212
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Orthopaedic surgery
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: Ohba Seiko 東京医科歯科大学, 大学院医歯学総合研究科, 非常勤講師 (60710118)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000); Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
• Keywords: 骨細胞 / 骨芽細胞 / RAS / 骨代謝 / レニン・アンジオテンシン

Outline of Final Research Achievements

In this study, we evaluated the role of RAS receptor in osteoblast and osteocyte. Osteocyte specific RAS receptor knockout mice (CKO) showed increase of cortical bone mass. On the other hand, osteoblast specific knock out mice did not show the bone abnormality. Furthermore, we analyzed the target genes of the RAS receptor in osteocytes by comprehensive gene analysis. We are now trying to examine the physiological function of those target genes in osteocytes.